Indivior Pharmaceuticals (INDV) Liabilities and Shareholders Equity (2021 - 2026)

Indivior Pharmaceuticals' Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 12.95% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $5.3 billion (up 95.69% YoY), while the FY2025 annual figure was $1.2 billion, down 8.74% from the prior year.
• Liabilities and Shareholders Equity was $1.2 billion for Q1 2026 at Indivior Pharmaceuticals, roughly flat from $1.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q4 2022 to a low of $1.2 billion in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2025.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity decreased 0.62% in 2023, then declined 25.14% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.8 billion in 2022, then decreased by 0.62% to $1.8 billion in 2023, then retreated by 25.14% to $1.3 billion in 2024, then retreated by 8.74% to $1.2 billion in 2025, then retreated by 0.33% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.